Autolus Narrows Q3 Loss Amid AUCATZYL Launch, Cash Drains

Ticker: AUTL · Form: 10-Q · Filed: 2025-11-12T00:00:00.000Z

Sentiment: mixed

Topics: Biotechnology, CAR-T Therapy, Oncology, Commercialization, Cash Burn, Net Loss, Revenue Growth

Related Tickers: AUTL, BNTX

TL;DR

**Autolus is finally generating revenue from AUCATZYL, but the cash burn is alarming, making future financing a near certainty.**

AI Summary

Autolus Therapeutics plc reported a net loss of $79.1 million for the three months ended September 30, 2025, a slight improvement from the $82.1 million net loss in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $197.2 million, compared to $193.1 million in 2024. The company generated product revenue, net, of $21.1 million in Q3 2025 and $51.0 million for the nine months, a significant increase from zero in the prior year periods, driven by the commercialization of AUCATZYL. However, cost of sales surged to $28.6 million in Q3 2025 and $71.0 million for the nine months. Research and development expenses decreased by 30.8% to $27.9 million in Q3 2025 from $40.3 million in Q3 2024, and by 23.7% to $82.1 million for the nine months from $107.6 million. Selling, general and administrative expenses increased substantially by 32.7% to $36.3 million in Q3 2025 and by 42.5% to $96.1 million for the nine months, reflecting commercialization efforts. Cash and cash equivalents decreased from $227.4 million at December 31, 2024, to $86.1 million at September 30, 2025, with net cash used in operating activities totaling $216.2 million for the nine-month period.

Why It Matters

Autolus's first product revenue from AUCATZYL is a critical milestone, signaling a shift from pure R&D to commercialization, which could significantly impact its long-term viability and competitive standing against other CAR-T developers. The substantial increase in selling, general and administrative expenses and cost of sales indicates the heavy investment required for market entry, which investors need to monitor closely for return on investment. The rapid decline in cash and cash equivalents, coupled with ongoing net losses, suggests potential future financing needs, which could dilute existing shareholders. For patients, the successful launch of AUCATZYL offers a new therapeutic option for relapsed or refractory B-cell precursor acute lymphoblastic leukemia, potentially improving outcomes in a challenging disease area.

Risk Assessment

Risk Level: high — The company reported a net loss of $197.2 million for the nine months ended September 30, 2025, and its cash and cash equivalents plummeted from $227.4 million at December 31, 2024, to $86.1 million at September 30, 2025. Net cash used in operating activities was $216.2 million for the nine-month period, indicating a significant ongoing cash drain that will necessitate further funding.

Analyst Insight

Investors should closely monitor Autolus's cash burn rate and future financing plans, as significant dilution is a strong possibility. While AUCATZYL's initial revenue is positive, the high cost of sales and SG&A expenses suggest profitability is still distant. Consider the company's ability to scale AUCATZYL sales and manage operational costs before making further investments.

Key Numbers

Key Players & Entities

FAQ

What were Autolus Therapeutics' key financial results for Q3 2025?

Autolus Therapeutics plc reported product revenue, net, of $21.1 million for the three months ended September 30, 2025. The company's net loss for the quarter was $79.1 million, an improvement from the $82.1 million net loss in Q3 2024.

How has Autolus's revenue changed year-over-year for the nine months ended September 30, 2025?

For the nine months ended September 30, 2025, Autolus generated $51.0 million in product revenue, net, a significant increase from zero revenue in the same period of 2024. This marks the first substantial revenue from their commercial product, AUCATZYL.

What is the current cash position of Autolus Therapeutics?

As of September 30, 2025, Autolus Therapeutics plc had cash and cash equivalents of $86.1 million. This represents a substantial decrease from $227.4 million at December 31, 2024.

Why did Autolus's selling, general and administrative expenses increase in 2025?

Selling, general and administrative expenses increased by 42.5% to $96.1 million for the nine months ended September 30, 2025, from $67.4 million in the prior year. This rise is primarily attributable to increased commercialization activities and infrastructure build-out for AUCATZYL.

What are the main risks highlighted in Autolus's 10-Q filing?

The filing highlights risks related to generating revenue from AUCATZYL, maintaining regulatory approval, the timing and results of clinical trials, and the need for additional financing. The significant cash burn of $216.2 million from operating activities for the nine months ended September 30, 2025, is a key financial risk.

How did Autolus's research and development expenses change in 2025?

Research and development expenses decreased by 23.7% to $82.1 million for the nine months ended September 30, 2025, compared to $107.6 million in the same period of 2024. This reduction suggests a potential shift in resource allocation as AUCATZYL moves into commercialization.

What is AUCATZYL and its significance for Autolus?

AUCATZYL (obecabtagene autoleucel) is Autolus's commercial product for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Its successful launch and revenue generation are critical for the company's transition from a development-stage biotech to a commercial entity.

What is the impact of foreign exchange on Autolus's financial results?

For the nine months ended September 30, 2025, Autolus reported foreign exchange gains, net, of $1.8 million, a positive shift from losses of $12.4 million in the same period of 2024. However, foreign currency exchange translation adjustment resulted in a gain of $23.8 million in other comprehensive income.

What is Autolus's strategy for commercializing AUCATZYL?

Autolus's strategy involves generating revenue from AUCATZYL by maintaining significant market acceptance among physicians, patients, and healthcare payors. This includes expanding into additional territories and building out sales and marketing personnel, as evidenced by the increase in SG&A expenses.

What should investors consider regarding Autolus's future funding needs?

Given the net cash used in operating activities of $216.2 million for the nine months ended September 30, 2025, and a cash balance of $86.1 million, investors should anticipate that Autolus will likely need to secure additional funding in the near future, which could lead to shareholder dilution.

Filing Stats: 4,641 words · 19 min read · ~15 pages · Grade level 20 · Accepted 2025-11-12 16:22:03

Key Financial Figures

Filing Documents

– Financial Information

Part I – Financial Information 6

Financial I nformation

Item 1. Financial I nformation 6 Condensed Consolidated Balance Sheets as of September 30, 2025 (Unaudited) and December 31, 2024 6 Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended September 30, 2025 and 2024 (Unaudited) 7 Condensed Consolidated Statements of Changes in Shareholders' Equity for the Three and Nine Months Ended September 30, 2025 and 2024 (Unaudited) 8 Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 and 2024 (Unaudited) 10 Notes to the Unaudited Condensed Consolidated Interim Financial Statements 12

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 33

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 48

Controls and Procedures

Item 4. Controls and Procedures 49

– Other Information

Part II – Other Information 49

Legal Proceedings

Item 1. Legal Proceedings 49

Risk Factors

Item 1A. Risk Factors 49

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 52

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 52

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 52

Other Information

Item 5. Other Information 52

Exhibits

Item 6. Exhibits 53

Signatures

Signatures 53 GENERAL INFORMATION Unless context otherwise requires, all references in this Quarterly Report on Form 10-Q to "Autolus," the "Group," the "company," "we," "us" and "our" refer to Autolus Therapeutics plc and its consolidated subsidiaries, except where the context otherwise requires. Autolus, AUCATZYL and our other trademarks or service marks appearing in this Quarterly Report on Form 10-Q are our property. Solely for convenience, the trademarks and trade names in this Quarterly Report on Form 10-Q are referred to without the and TM symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. Products or service names of other companies mentioned in this Quarterly Report on Form 10-Q may be trademarks, trade names or service marks of their respective owners. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future financial condition, future operations, research and development costs, plans and objectives of management, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "aim," "anticipate," "assume," "believe," "contemplate," "continue," "could," "design," "due," "estimate," "expect," "goal," "intend," "may," "objective," "plan," "predict," "positioned," "potential," "seek," "should," "target," "will," "would" and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. Although we believe that we have a reasonable basis for each forward-looking statement contained in

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

Financial statements

Item 1. Financial statements AUTOLUS THERAPEUTICS PLC Unaudited Condensed Consolidated Balance Sheets (In thousands, except share and per share amounts) Note September 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 86,124 $ 227,380 Marketable securities - Available-for-sale debt securities 7 281,289 360,643 Restricted cash 1,498 1,425 Accounts receivable, net 3 32,604 15 Inventories, net 8 27,723 4,138 Prepaid expenses and other current assets 9 85,339 67,328 Total current assets 514,577 660,929 Non-current assets: Property and equipment, net 10 66,851 49,553 Intangible assets, net 11 20,283 12,373 Prepaid expenses and other non-current assets 191 170 Operating lease right-of-use assets, net 56,625 55,498 Long-term deposits 1,031 963 Deferred tax asset 2,389 3,239 Total assets $ 661,947 $ 782,725 Liabilities and shareholders' equity Current liabilities: Accounts payable $ 10,967 $ 1,969 Accrued expenses and other liabilities 12 52,264 52,276 Deferred revenue 3 7,612 — Operating lease liabilities, current 4,828 2,998 Liabilities related to future royalties and milestones, net - current 15 7,400 3,500 Total current liabilities 83,071 60,743 Non-current liabilities: Operating lease liabilities, non-current 61,007 49,631 Liabilities related to future royalties and milestones, net - non-current 15 251,945 244,600 Other long-term payables 472 426 Total liabilities 396,495 355,400 Commitments and contingencies 17 Shareholders' equity: Ordinary shares, $ 0.000042 par value; 490,909,783 and 490,909,783 shares authorized as of September 30, 2025 and as of December 31, 2024, respectively; 266,141,411 and 266,121,689 , shares issued at September 30, 2025 and December 31, 2024, respectively; 266,143,286 and 266,125,337 , shares outstanding at September 30, 2025 and December 31, 2024, respectively 12 12 Deferred shares, 0.00001 par value; 34,425 shares authorized, issued and outsta

View on Read The Filing